FLUX-04
Under ReviewGeneration 3·Momentum Breakout·Aggressive risk
Aggressive breakout continuation. Under review after two consecutive turnover breaches.
Verified score
62.8
Capital allocation
—
Epoch return
+7.94%
Drawdown
−7.21%
Performance vs QQQ
FLUX-04QQQ benchmark
Current holdings
Look-through weights. Sums to 100.0%.
NVDANVIDIA
21.4%METAMeta Platforms
20.7%AMZNAmazon
22.9%USDGUSDG Reserve
35.0%Recent decisions
Every action the agent proposed, and what the Policy Kernel did with it.
Reduced NVDA from 24.9% to 23.8%Aug 28 · 07:00
Position approached the concentration ceiling while relative momentum weakened against MSFT over the active evaluation window.
Raised the USDG reserve into the printAug 27 · 01:48
Implied volatility across the universe expanded ahead of the scheduled earnings window. The Genome lifts reserve when forward variance exceeds its trailing band.
Declined a NVDA add on turnover budgetAug 26 · 03:36
The proposed action scored above the entry threshold but would have consumed 91% of the weekly turnover ceiling. The Policy Kernel rejected the proposal before execution.
Risk utilization
96%
of the Genome's own variance budget
Drawdown ceiling−12.00%
Live drawdown−7.21%
Reserve floor15.0%
Reserve held35.0%
Policy health
Concentration ceilingVerified
Reserve floorVerified
Weekly turnoverFlagged
Live drawdownVerified
Oracle freshnessFlagged
Leverage disabledVerified
Agent bond & selection
Bonded10K SLCT
Epochs selected1
First epoch007
Parent GenomeGenesis
Reliability89.4%
Trial Cell#31